bezafibrate has been researched along with Metabolic Syndrome in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (70.59) | 29.6817 |
| 2010's | 5 (29.41) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ackerman, Z; Amir, G; Grozovski, M; Oron-Herman, M; Rosenthal, T; Sela, BA | 1 |
| Ito, H; Kohno, K; Miyoshi, T; Morita, H; Nakamura, K; Noda, Y; Oe, H; Ohno, Y; Toh, N | 1 |
| Fisman, EZ; Goldenberg, I; Klempfner, R; Peled, Y; Shlomo, N; Tenenbaum, A; Tzur, B; Younis, A | 1 |
| Davidson, MH | 1 |
| Behar, S; Boyko, V; Brodov, Y; Chouraqui, P | 1 |
| Aburada, M; Hokao, R; Iizuka, S; Makihara, H; Sasaki, Y; Shimada, T; Suzuki, W; Teraoka, R; Tsuneyama, K | 1 |
| Kotake, H | 1 |
| Boden, WE | 1 |
| Oron-Herman, M; Rosenthal, T; Sela, BA | 1 |
| Behar, S; Boyko, V; Fisman, EZ; Motro, M; Tanne, D; Tenenbaum, A | 1 |
| Bulut, D; Bulut-Streich, N; Graf, C; Hanefeld, C; Mügge, A; Spiecker, M | 1 |
| Fujioka, D; Ichigi, Y; Kawabata, K; Kitta, Y; Kodama, Y; Kugiyama, K; Mende, A; Nakamura, T; Obata, JE; Saito, Y; Takano, H; Umetani, K | 1 |
| Loewen, P; McCormack, J | 1 |
| Adler, Y; Behar, S; Benderly, M; Fisman, EZ; Fujita, K; Funahashi, T; Hibuse, T; Hiuge, A; Kihara, S; Kumada, M; Maeda, N; Matas, Z; Motro, M; Nishizawa, H; Shimomura, I; Tanne, D; Tenenbaum, A | 1 |
| Inokuchi, T; Ka, T; Kobayashi, T; Moriwaki, Y; Takahashi, S; Tsutsumi, Z; Yamamoto, T | 1 |
| Ackerman, Z; Grozovski, M; Link, G; Oron-Herman, M; Pappo, O; Rosenthal, T; Sela, BA | 1 |
3 review(s) available for bezafibrate and Metabolic Syndrome
| Article | Year |
|---|---|
[Syndrome X].
Topics: Animals; Bezafibrate; Biguanides; Fatty Acids, Nonesterified; Humans; Hyperglycemia; Hyperinsulinism; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Leptin; Life Style; Metabolic Syndrome; Pioglitazone; Thiazoles; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2002 |
Therapeutic implications of recent ATP III guidelines and the important role of combination therapy in total dyslipidemia management.
Topics: Bezafibrate; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetic Angiopathies; Drug Therapy, Combination; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Metabolic Syndrome; Practice Guidelines as Topic | 2003 |
Role of fibrates in reducing coronary risk: a UK Consensus.
Topics: Bezafibrate; Cholesterol, HDL; Coronary Disease; Drug Therapy, Combination; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Metabolic Syndrome | 2004 |
6 trial(s) available for bezafibrate and Metabolic Syndrome
| Article | Year |
|---|---|
Bezafibrate improves postprandial hypertriglyceridemia and associated endothelial dysfunction in patients with metabolic syndrome: a randomized crossover study.
Topics: Adult; Bezafibrate; Cross-Over Studies; Endothelium, Vascular; Female; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Male; Metabolic Syndrome; Middle Aged; Postprandial Period; Single-Blind Method | 2014 |
Effect of the metabolic syndrome and hyperuricemia on outcome in patients with coronary artery disease (from the Bezafibrate Infarction Prevention Study).
Topics: Aged; Bezafibrate; Blood Glucose; Coronary Artery Disease; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Hyperuricemia; Hypolipidemic Agents; Incidence; Israel; Male; Metabolic Syndrome; Middle Aged; Myocardial Infarction; Prognosis; Retrospective Studies; Risk Factors; Survival Rate; Triglycerides; Uric Acid | 2010 |
Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome.
Topics: Adult; Aged; Bezafibrate; Blood Glucose; Blood Pressure; Body Mass Index; Female; Follow-Up Studies; Humans; Hypolipidemic Agents; Incidence; Lipids; Male; Metabolic Syndrome; Middle Aged; Myocardial Infarction; Retrospective Studies; Risk Factors; Survival Rate; Treatment Outcome | 2005 |
Remnant lipoproteinemia is a risk factor for endothelial vasomotor dysfunction and coronary artery disease in metabolic syndrome.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Bezafibrate; Biomarkers; Cholesterol; Coronary Artery Disease; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Lipoproteins; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Risk Factors; Triglycerides; Vasodilation | 2005 |
Effects of peroxisome proliferator-activated receptor ligands, bezafibrate and fenofibrate, on adiponectin level.
Topics: Adipocytes; Adiponectin; Adult; Analysis of Variance; Animals; Bezafibrate; Cells, Cultured; Disease Models, Animal; Double-Blind Method; Female; Fenofibrate; Gene Expression Regulation; Humans; Hypolipidemic Agents; Ligands; Male; Metabolic Syndrome; Mice; Mice, Knockout; Middle Aged; Peroxisome Proliferator-Activated Receptors; Probability; Prospective Studies; RNA, Messenger; Statistics, Nonparametric; Stromal Cells | 2007 |
Relationship between insulin resistance and low urinary pH in patients with gout, and effects of PPARalpha agonists on urine pH.
Topics: Bezafibrate; Biomarkers; Body Mass Index; Fenofibrate; Gout; Humans; Hydrogen-Ion Concentration; Hypolipidemic Agents; Insulin Resistance; Male; Metabolic Syndrome; Middle Aged; Nephrolithiasis; PPAR alpha; Regression Analysis; Triglycerides; Uric Acid | 2007 |
8 other study(ies) available for bezafibrate and Metabolic Syndrome
| Article | Year |
|---|---|
Effects of antihypertensive and triglyceride lowering agents on splenocyte apoptosis in rats with fatty liver.
Topics: Amlodipine; Animals; Antihypertensive Agents; Apoptosis; Bezafibrate; Blood Pressure; Captopril; Caspase 3; Fatty Liver; Hypolipidemic Agents; Lipids; Male; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Rats; Rats, Sprague-Dawley; Spleen; Triglycerides | 2013 |
Metabolic syndrome is independently associated with increased 20-year mortality in patients with stable coronary artery disease.
Topics: Age Factors; Aged; Bezafibrate; Chi-Square Distribution; Coronary Artery Disease; Female; Humans; Hypolipidemic Agents; Kaplan-Meier Estimate; Male; Metabolic Syndrome; Middle Aged; Multivariate Analysis; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic; Registries; Renal Insufficiency; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors | 2016 |
A clinical puzzle: fibrates and homocysteine elevation: editorial to: "fibrates may cause an abnormal urinary betaine loss which is associated with elevations in plasma homocysteine" by M. Lever et al.
Topics: Animals; Betaine; Bezafibrate; Clofibric Acid; Dyslipidemias; Folic Acid; Homocysteine; Humans; Hypolipidemic Agents; Metabolic Syndrome | 2009 |
Effects of bezafibrate in nonalcoholic steatohepatitis model mice with monosodium glutamate-induced metabolic syndrome.
Topics: Adipose Tissue; Animals; Bezafibrate; Diabetes Mellitus; Disease Models, Animal; Eating; Fatty Liver; Gene Expression Regulation; Glucose Tolerance Test; Glycosuria; Hypolipidemic Agents; Lipid Metabolism; Liver; Male; Metabolic Syndrome; Mice; Non-alcoholic Fatty Liver Disease; Obesity; Organ Size; RNA, Messenger; Sodium Glutamate | 2011 |
Risk reduction therapy for syndrome X: comparison of several treatments.
Topics: Amlodipine; Animals; Antihypertensive Agents; Bezafibrate; Blood Pressure; Body Weight; Captopril; Fructose; Hydrolases; Hypertension; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Male; Metabolic Syndrome; Rats; Rats, Sprague-Dawley; Risk Reduction Behavior; Rosiglitazone; Thiazolidinediones; Triglycerides | 2005 |
Comparison of endothelial function in patients with metabolic syndrome on bezafibrate or atorvastatin therapy.
Topics: Aged; Atorvastatin; Bezafibrate; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Coronary Circulation; Endothelium, Vascular; Forearm; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Hypolipidemic Agents; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Regional Blood Flow; Treatment Outcome; Vasodilation | 2005 |
The other side of the bezafibrate infarction prevention trial data.
Topics: Bezafibrate; Comorbidity; Humans; Hypolipidemic Agents; Incidence; Metabolic Syndrome; Myocardial Infarction; Preventive Medicine; Risk Factors | 2005 |
Effects of amlodipine, captopril, and bezafibrate on oxidative milieu in rats with fatty liver.
Topics: Amlodipine; Animals; Antihypertensive Agents; Bezafibrate; Captopril; Fatty Liver; Fructose; Hypolipidemic Agents; Male; Metabolic Syndrome; Oxidative Stress; Rats; Rats, Sprague-Dawley | 2008 |